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A B S T R A C T
Purpose: To evaluate evolution and elucidate clinical phenotypes related to prognosis of patients with
mesial temporal lobe epilepsy related to hippocampal sclerosis (MTLE-HS) treated exclusively with
antiepileptic drugs (AED).
Methods: Forty-seven out of 68 MTLE-HS patients treated between January 2005 and June 2010 were
retrospectively studied for demographic, clinical and outcome data. The population was divided into
drug-responder and drug-resistant patients; the latter was divided, according to the duration of the
seizure-free periods along their evolution, into patients with at least one seizure-free period longer than
one year and those with shorter periods. Variables were compared between drug-responders vs drug-
resistants and drug-resistants with long seizure-free periods vs drug-resistants without it.
Results: There were 7 (15%) drug-responders, 39 (83%) drug-resistants and 1 patient (2%) with an
undetermined response. Eighteen (46%) drug-resistant individuals had seizure-free periods longer than
one year, with mean duration of 46 months (3.8 years). Since no factor was statistically associated with
long seizure-free period within drug-resistants, we can clinically distinguish two phenotypes: women
with left HS and late onset of seizures, with poor prognosis, and men with right HS and earlier
appearance of seizures, attaining a better outcome. Twenty out of 47 (42.5%) patients followed an
intermittent pattern of epilepsy.
Conclusions: Non-surgical MTLE-HS drug-resistant patients can achieve long seizure-free periods with
AED, but relapses are common. Female gender, left or bilateral lesion and later onset of seizures seem to
be bad prognosis factors within MTLE-HS drug-resistant patients.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Hippocampal sclerosis (HS) is the most common lesion
underlying mesial temporal lobe epilepsy (MTLE).1,2 It is found
in 50–70% of patients with temporal lobectomies.1 Atrophy
associated with loss of neurons and gliosis in hippocampal areas
are histological hallmarks of HS.3 The underlying pathophysiologi-
cal mechanism is not well established,2,4 but the outcome is a
speciﬁc damage of the temporo-mesial structures.5 MTLE-HS
seems to have bad prognosis6 and seizures are frequently
associated with medically intractability, especially with a back-
ground of febrile convulsions.7 Apart from seizures, patients may* Corresponding author. Tel.: +34 696621400; fax: +34 948296500.
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http://dx.doi.org/10.1016/j.seizure.2012.09.010manifest subtle neuropsychological deﬁcits, such as impaired
facial emotion recognition.8,9
Magnetic Resonance Imaging (MRI) is the most valuable
imaging technique for diagnosing MTLE-HS.10,11 Increased hippo-
campal signal on T2-weighted images, decreased signal on T1-
weighted images and hippocampal atrophy are features that allow
us to diagnose HS in 80–90% of patients.12 Therefore, the role of
MRI in prognosis is not clear. On the one hand, a more widespread
gray-matter atrophy, out of temporal lobe, has been recently
described in drug-resistant patients;13 on the other hand, up to 40%
of patients with sporadic ‘‘benign’’ temporal lobe epilepsy have HS
by MRI.14
Surgical treatment with amigdalo-hippocampectomy is the
cornerstone of the treatment of MTLE-HS15 at any age, whenever
the patient is considered as a good candidate after presurgical
evaluation.16 Noteworthy, certain MTLE-HS patients are not
considered optimal to undergo surgery for some reasons: bilateral
lesions, high risk of post-surgery neuropsychological deﬁcits or
rejection of patients themselves. There are few reports concerningvier Ltd. All rights reserved.
Table 1
Baseline features of patients.
Variables Mean  SD or n (%)
Age (year) 44.02  12.4
Age of ﬁrst seizure (year) 19.3  15.2
Evolution (year) 24.2  13.7
Gender
Male 15 (32)
Female 32 (68)
Familiar history of epilepsy 8 (17)
Perinatal injury 8 (17)
Febrile convulsions 12 (25.5)
Generalized seizures 42 (89)
EEG abnormalities 26 (55)
Side of HS
Right 20 (43)
Left 23 (49)
Bilateral 4 (8)
Response to AED
Responders 7 (15)
Resistants 39 (83)
Indetermined 1 (2)
Periods > 1 year seizure free 25 (53)
S.D., standard deviation; EEG, electroencephalogram; HS, hippocampal sclerosis;
AED, antiepileptic drugs.
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antiepileptic drugs (AED). Furthermore, non-surgical MTLE-HS
patients are frequently considered as a homogeneous array with
bad prognosis, which can mislead us when we are dealing with an
individual patient. Therefore, the aim of the present study is to
describe different clinical phenotypes of non-surgical MTLE-HS
patients that allow us to forecast more accurately their future
evolution in terms of seizures.
2. Methods
2.1. Clinical assessment
We reviewed 68 patients diagnosed of MTLE-HS in the Epilepsy
Unit of the Clinica Universidad de Navarra (Pamplona, Spain) from
January 2005 to June 2010. Diagnosis was established according to
the League Against Epilepsy criteria,17 through a detailed
neurologic evaluation based on clinical features and MRI evidence
of HS.
Non-surgical patients were selected for further studies. For each
one, we collected the variables of interest by reviewing medical
records. Data included demography (age and gender), risk factors
for epilepsy (family history, background of perinatal distress and
febrile convulsions), clinical features (age at ﬁrst seizure, presence
of secondarily generalized seizures, epileptic discharges in EEG and
side of HS in MRI) and AED regimen with its response.
To determine the AED response, we used the recently published
deﬁnition of drug-resistant epilepsy. It was deﬁned as failure of
adequate trials of two tolerated, appropriately chosen and used
AEDs schedules (whether as monotherapy or in combination) to
achieve sustained seizure freedom. Seizure freedom was deﬁned as
a period without seizures for a minimum of three times the longest
preintervention interseizure interval (determined from seizures
occurring within the past 12 months) or 12 months, whichever is
longer.18
In addition, seizure patterns of relapse and remission were
determined, according with a recently published paper.19 Patients
were categorized into two groups: continuous pattern, with no
period of remission, and intermittent pattern, in which patients
had at least one period of remission. Remission was deﬁned as the
presence of a period of at least two years without seizures.
2.2. Statistical analysis
Distribution of the variables was studied using the Kolmogorov
Smirnoff test method. In the ﬁrst step we compared baseline
demographic and clinical characteristics between drug-responder
and drug-resistant patients. In a second step, we compared the
same variables between drug-resistant patients with at least one
seizure-free period longer than one year and drug-resistant
patients without it. All variables followed a parametric distribution
and were studied by independent Sample t-test (two variables) in
ordinal variables and Chi Square in categorical variables. After-
wards, all variables were studied by binary logistic regression and
adjusted by age of onset and years of epilepsy evolution to
determine the risk of a poor response to AED and a lack of periods
longer than one year without seizures. Statistical analysis were
performed using the Statistical Package for the Social Sciences
(SPSS) version 16.0; p values of <0.05 were regarded as signiﬁcant.
3. Results
3.1. Baseline features
We collected data of 47 non-surgical MTLE-HS patients
(15 males, 32 females). Age at the time of evaluation rangedbetween 22 and 71 years (mean  SD: 44  12.4). Epilepsy onset age
was known in 39 patients and the mean was 19.3  15.2 years (range:
1–52); the mean disease evolution reached 24.2  13.7 years (range:
1–46). The background revealed familiar history of epilepsy in 8
(17%), perinatal injury in 8 (17%) and febrile convulsions in 12 (25.5%)
patients. Forty-two (89%) subjects had secondarily generalized tonic–
clonic seizures and EEG showed interictal epileptiform discharges in
26 (55%) patients. HS was unilateral in 43 patients (20 in right lobe
and 23 in left lobe) and 4 patients had bilateral damage.
Globally, patients were treated with 18 different AED, with a
mean of 5 each one (range 1–13). Most used drugs were
carbamazepine (CBZ) in 32, lamotrigine (LTG) in 28, valproic acid
(VPA) in 28 and levetiracetam (LEV) in 26 individuals. Taking into
account the deﬁnitions described above, 39 patients were drug-
resistant (83%), 7 drug-responder (15%) and 1 had an undeter-
mined response (2%). Baseline features data are summarized in
Table 1.
We found 25/47 subjects (53%) with at least one seizure-free
period longer than one year: 7 drug-responder and 18 drug-
resistant. Mean duration of these intervals was 59 months (almost
5 years). At the time we ﬁnished the study, periods reached 93
months (more than 7 years) for drug-responder patients and 46
months (almost 4 years) for drug-resistant ones. Regarding to AED
schedule, six drug-responder patients were on monotherapy, with
CBZ (2), VPA (1), LTG (1), phenytoin (PHT [1]) and oxcarbazepine
(OXC [1]); the only patient on bitherapy was on VPA plus
topiramate (TPM). Concerning to the 18 drug-resistant patients, 8
(44%) were on monotherapy (CBZ, OXC, VPA or LEV), 6 (33%) on
bitherapy (CBZ was the most used AED) and 4 (23%) on three AED.
At the end of the follow-up, 31 patients (66%) continued having
seizures, whereas 16 (34%) had become seizure-free. Four patients
achieved this condition with the ﬁrst AED tried (VPA, LTG, PHT and
OXC), 3 patients on bitherapy and 9 patients tried more than 2
AEDs before attaining seizure freedom.
3.2. Clinical phenotypes based on response to AED
Proportion of females was higher in drug-resistant patients
group than in drug-responder one (74% vs 29%; p = 0.029). Side of
HS was different in drug-responders than in drug-resistant
patients, with higher frequency of subjects with left or bilateral
HS in patients with poor response to AED (64% vs 14%; p = 0.033).
Table 2
Clinical factors and comparison between different groups of MTLE-HS patients.
Variables Mean  SD or n (%) p-Value Mean  SD or n (%) p-Value
Drug-responders Drug-resistants Drug-resistants >
1 year seizure free
Drug-resistants
< 1 year seizure free
Age (year) 43.1  12.2 44.4  12.7 0.81 43  13.3 45.6  12.3 0.53
Age of ﬁrst seizure (year) 18  13.8 19.1  15.7 0.87 15.5  11.3 22.4  18.7 0.22
Evolution (year) 27.9  11.5 24.1  13.7 0.5 25.9  13 22.6  13.7 0.49
Gender
Male 5 (71) 10 (26) 0.029* 6 (33) 4 (19) 0.46
Female 2 (29) 29 (74) 12 (67) 17 (81)
Familiar history of epilepsy 2 (29) 5 (13) 0.29 1 (6) 4 (19) n.p.
Perinatal injury 1 (14) 7 (18) n.p. 4 (22) 3 (14) 0.68
Febrile convulsions 2 (29) 10 (26) n.p. 5 (28) 5 (24) 1
Generalized seizures 6 (86) 35 (90) 1 16 (89) 19 (90.5) 1
EEG abnormalities 2 (29) 23 (59) n.p. 10 (56) 13 (62) 0.54
Side of HS
Right 6 (86) 14 (36) 0.033* 8 (44) 6 (29) 0.34
Left 0 (0) 22 (56) 10 (56) 12 (57)
Bilateral 1 (14) 3 (8) 0 (0) 3 (14)
MTLE, mesial temporal lobe epilepsy; HS, hippocampal sclerosis; S.D., standard deviation; EEG, electroencephalogram; AED, antiepileptic drugs.
Parametric test used for analysis were t-student or Chi square.
n.p.: non performed due to small number in a group (2 patients).
* p values of < 0.05 were regarded as signiﬁcant.
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signiﬁcant differences between drug-responders and drug-resis-
tant individuals. Logistic regression analysis was not performed
due to the unbalanced number of patients in each group, which
could lead to mistaken association.
Within drug-resistant patients group, we did not ﬁnd statisti-
cally signiﬁcant differences comparing drug-resistant subjects
with a seizure-free period longer than one year with those who did
not achieve that seizure freedom gap. Moreover, logistic regression
did neither show any clinical factor signiﬁcantly associated with
higher resistance. Nonetheless, some features showed a tendency:
patients without seizure freedom periods were more frequently
women (81% vs 67%; p = 0.46), they had their ﬁrst seizure later
(22.4 years vs 15.5; p = 0.22) and their MRI showed more
frequently left HS (71% vs 56%; p = 0.34). These results are detailed
in Table 2.
3.3. Patterns of evolution
Following the patterns of evolution in people with refractory
epilepsy described by Neligan et al.,19 we found 27 patients (57.5%)
developing a continuous pattern, whereas 20 (42.5%) had an
intermittent pattern with at least one period of two years without
seizures.
4. Discussion
MTLE-HS is a usually refractory epilepsy6 and surgical
treatment, mainly amygdalohippocampectomy, should be kept
on mind of neurologists when managing this disease.15 Nonethe-
less, several reasons lead some patients to be treated only
medically, without any surgery. In this retrospective study, we
evaluate the evolution over years in a cohort of patients with
MTLE-HS treated exclusively with AED.
First of all, we discovered that more than half of patients with
MTLE-HS (25 out of 47; 53%) had at least one seizure-free period
longer than one year, with a mean period without seizures of
nearly 5 years. Globally, at the end of follow-up, 16 patients (34%)
were seizure free, 7 drug-responder and 9 initially drug-resistant
patients. In a subsequent review of our data performed in 2012, all
drug-responder patients kept without seizures and on the same
treatment; further, one drug-resistant patient underwent an
amygdalohippocampectomy in 2011 and remains without seizures6 months later. These data are concordant with previous reports,
where the rate of complete remission ranged from 5% to
42%.2,3,6,20–22
Focusing on the 39 drug-resistant patients who were deemed
not to be suitable for epilepsy surgery, 18 (46%) became seizure
free for at least 1 year; 13 (33%) attained any remission period (2
years without seizures) and 9 (23%) were seizure free at the end of
the study. Mean time of periods without seizures was 46 months
(almost 4 years). We wish to highlight the signiﬁcance of these
ﬁgures: approximately one half of non-surgical drug-resistant
patients with MTLE-HS could reach a seizure-free period of at least
one year. From these, one half had relapses after that long period
without seizures, but the other half (around 25% of all drug-
resistant patients) achieved complete control with AED. In our
opinion, these ﬁndings support the notion that the natural history
of MTLE-HS is not straightforward.4 Intractability, therefore, is
preceded in some cases by quiescent periods along some years.
This phenomenon points to an underlying progressive damage in
the whole brain, not only in mesial structures.23 With AED
treatment we are only facing the evident outcome of the disease,
namely seizures, but not the epileptogenic events involving a set of
cellular, molecular, immunological and genetic changes that shift a
normal brain tissue to an epileptic one.
Previous studies have pointed to early history of head trauma,
female gender, mental retardation2 and higher initial seizure
frequency13 as bad prognostic features related to poorer control of
seizures. We also encountered females developed a more
refractory epilepsy. The prognostic role of an early age of seizure
onset is contradictory; some studies state that is a good prognosis
factor,21 while others establish the opposite.2,7,22 Our results do
not show any difference in that regard. Concerning the side of HS,
there is no signiﬁcant interaction between the side of the lesion
and resistance in adults.2,22 However, Lindsay et al. described that,
in pediatric population, patients with left sided lesions had poorer
outcome.24 In our study, performed in adults, none of the drug-
responder patients has unilateral left HS, whereas most of the
drug-resistant ones (64%) have a damaged left temporal lobe
(unilateral or associated with right HS). Then, since we do not ﬁnd
statistical association, probably due to small number of patients in
the drug-responders group, it seems to be a trend to refractoriness
in MTLE-HS patients with left damage. Concerning to clinical
prognosis factor to predict seizure-free period longer than one year
within drug-resistant patients, we have not found any with
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cance and we hypothesize two phenotypes within non-surgical
MTLE-HS patients: (a) women with left HS whose ﬁrst seizure
occurred approximately at the age of 20 years-old have less chance
to have long periods without seizures; (b) men with right HS
whose ﬁrst seizure appeared when at the age of 15 years-old have
higher probability to remain long time free of seizures. The
different evolution of these two subgroups is not well understood
and suggests a distinct pattern of epileptogenic development. The
elements described above are probably the same, but the
interaction between each other could lead to different epileptic
charge with variations in the seizure threshold.
Additionally, 42.5% of non-surgical MTLE-HS patients devel-
oped an intermittent pattern of refractory epilepsy, with at least
one emission period.19 These results are slightly better than
described by Neligan et al. in 38 patients with MTLE-HS (34.2%).19
One explanation for the minimal difference could be that our
patients have exclusively HS, without any other lesion, but in their
study is not speciﬁed if patients have an additional damage, which
probably would have impaired the prognosis.
Our study has two main limitations: (a) it is a retrospective one;
(b) number of patients is too small to draw any deﬁnitive
conclusion, especially in the drug-responder patients group. On the
one hand, the retrospective view of data has the disadvantage that
some prognosis factors, which would be interesting to evaluate,
were not reported regularly in medical records. One example could
be neuropsychological data, which could reﬂect the functional
damage of the hippocampus. On the other hand, the small number
of patients makes the validity of statistical data questionable, and
the lack of signiﬁcance of items explored is likely closely related
with this limitation. This lack of patients has led us to establish
one-year without seizure as the cut-off for the patients to be
included in one or another group. In future studies with more
patients, one possibility is to set up different cut-offs and to seek
different clinical features for each one. Nevertheless, these results
can help to point at tendencies that should be tested with larger
cohorts of patients, even in multicentre studies including Epilepsy
Centres.
In short, approximately one half of non-surgical drug-resistant
patients with MTLE-HS could achieve long seizure-free periods
only with AED. Female gender and left or bilateral lesion seem to be
helpful to forecast the response of one individual patient. Within
drug-resistant patients, we have not ﬁnd any statistically
signiﬁcant factor to predict seizure-free period longer than one
year, but female gender, damage in the left hippocampus and later
onset of seizures are more frequent in patients without seizure
freedom period. Though we are dealing with a resistant sort of
epilepsy, different combinations of AED could elicit long periods of
seizure freedom with remission periods and an intermittent
seizure pattern. Nevertheless, 50% of these patients had relapses
and become intractable along the evolution of disease which
prompts to a dynamic underlying epileptogenic process over their
whole life.
Conﬂict of interest statement
None of the authors have any ﬁnancial or proprietary interest in
this article.
Acknowledgment
Asier Gomez-Iban˜ez is supported by the Aid Program for
Education and Training of Research Staff 2011–2012 grant from theBasque Country government to perform an Advanced Program
Training in Epilepsy at the Clinica Universidad de Navarra
(Pamplona, Spain).
References
1. Margerison JH, Corsellis JA. Epilepsy and the temporal lobes. A clinical, electro-
encephalographic and neuropathological study of the brain in epilepsy, with
particular reference to the temporal lobes. Brain 1966;89(September (3)):
499–530.
2. Varoglu AO, Saygi S, Acemoglu H, Ciger A. Prognosis of patients with mesial
temporal lobe epilepsy due to hippocampal sclerosis. Epilepsy Research
2009;85(August (2–3)):206–11.
3. Spencer SS. When should temporal-lobe epilepsy be treated surgically? Lancet
Neurology 2002;1(October (6)):375–82.
4. Berg AT. The natural history of mesial temporal lobe epilepsy. Current Opinion in
Neurology 2008;21(April (2)):173–8.
5. Cendes F, Andermann F, Gloor P, Lopes-Cendes I, Andermann E, Melanson D,
et al. Atrophy of mesial structures in patients with temporal lobe epilepsy:
cause or consequence of repeated seizures? Annals of Neurology 1993;34(De-
cember (6)):795–801.
6. Stephen LJ, Kwan P, Brodie MJ. Does the cause of localisation-related epilepsy
inﬂuence the response to antiepileptic drug treatment? Epilepsia 2001;42
(March (3)):357–62.
7. Pittau F, Bisulli F, Mai R, Fares JE, Vignatelli L, Labate A, et al. Prognostic factors
in patients with mesial temporal lobe epilepsy. Epilepsia 2009;50(January
(Suppl. 1)):41–4.
8. Meletti S, Benuzzi F, Rubboli G, Cantalupo G, Stanzani Maserati M, Nichelli P,
et al. Impaired facial emotion recognition in early-onset right mesial temporal
lobe epilepsy. Neurology 2003;60(February (3)):426–31.
9. Meletti S, Benuzzi F, Cantalupo G, Rubboli G, Tassinari CA, Nichelli P. Facial
emotion recognition impairment in chronic temporal lobe epilepsy. Epilepsia
2009;50(June (6)):1547–59.
10. Theodore WH, Katz D, Kufta C, Sato S, Patronas N, Smothers P, et al. Pathology of
temporal lobe foci: correlation with CT. MRI and PET Neurology 1990;40(May
(5)):797–803.
11. Dowd CF, Dillon WP, Barbaro NM, Laxer KD. Magnetic resonance imaging of
intractable complex partial seizures: pathologic and electroencephalographic
correlation. Epilepsia 1991;32(July–August (4)):454–9.
12. Jackson GD, Berkovic SF, Duncan JS, Connelly A. Optimizing the diagnosis of
hippocampal sclerosis using MR imaging. American Journal of Neuroradiology
1993;14(May–June (3)):753–62.
13. Bilevicius E, Yasuda CL, Silva MS, Guerreiro CA, Lopes-Cendes I,
Cendes F. Antiepileptic drug response in temporal lobe epilepsy: a clinical
and MRI morphometry study. Neurology 2010;75(November (19)):
1695–701.
14. Labate A, Ventura P, Gambardella A, Le Piane E, Colosimo E, Leggio U, et al. MRI
evidence of mesial temporal sclerosis in sporadic ‘‘benign’’ temporal lobe
epilepsy. Neurology 2006;66(February (4)):562–5.
15. Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized, controlled trial of
surgery for temporal-lobe epilepsy. New England Journal of Medicine 2001;345
(August (5)):311–8.
16. Murphy M, Smith PD, Wood M, Bowden S, O’Brien TJ, Bulluss KJ, et al.
Surgery for temporal lobe epilepsy associated with mesial temporal sclero-
sis in the older patient: a long-term follow-up. Epilepsia 2010;51(June
(6)):1024–9.
17. Proposal for revised classiﬁcation of epilepsies and epileptic syndromes. Com-
mission on Classiﬁcation and Terminology of the International League Against
Epilepsy. Epilepsia 1989;30(July–August (4)):389–99.
18. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al.
Deﬁnition of drug resistant epilepsy: consensus proposal by the ad hoc Task
Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51(June
(6)):1069–77.
19. Neligan A, Bell GS, Sander JW, Shorvon SD. How refractory is refractory
epilepsy? Patterns of relapse and remission in people with refractory epilepsy.
Epilepsy Research 2011;96(October (3)):225–30.
20. Semah F, Lamy C, Demeret S. Hippocampal sclerosis and other hippocampal
abnormalities in the early identiﬁcation of candidates for epilepsy surgery.
Archives of Neurology 2002;59(June (6)):1042–3. author reply 3.
21. Kumlien E, Doss RC, Gates JR. Treatment outcome in patients with mesial
temporal sclerosis. Seizure 2002;11(October (7)):413–7.
22. Kim WJ, Park SC, Lee SJ, Lee JH, Kim JY, Lee BI, et al. The prognosis for control of
seizures with medications in patients with MRI evidence for mesial temporal
sclerosis. Epilepsia 1999;40(March (3)):290–3.
23. Berg AT, Vickrey BG, Testa FM, Levy SR, Shinnar S, DiMario F, et al. How long
does it take for epilepsy to become intractable? A prospective investigation.
Annals of Neurology 2006;60(July (1)):73–9.
24. Lindsay J, Ounsted C, Richards P. Long-term outcome in children with temporal
lobe seizures. III: psychiatric aspects in childhood and adult life. Developmental
Medicine and Child Neurology 1979;21(October (5)):630–6.
